Lpathomab

Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].

Product Specifications

CAS Number

[1253114-37-2]

Product Name Alternative

LT3015; LT-3000

UNSPSC

12352203

Target

LPL Receptor

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Smiles

[Lpathomab]

References & Citations

[1]Visentin B, et al. Abstract# 1247: In vitro and in vivo efficacy of Lpathomab\# 8482; , a monoclonal antibody directed against lysophosphatidic acid (LPA), in ovarian cancer models[J]. Cancer Research, 2009, 69 (9_Supplement) : 1247-1247.|[2]Crack PJ, et al. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes. J Neuroinflammation. 2014 Feb 27;11:37.